---
title: "AFP.AU (AFP.AU) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AFP.AU/news.md"
symbol: "AFP.AU"
name: "AFP.AU"
parent: "https://longbridge.com/en/quote/AFP.AU.md"
datetime: "2026-06-04T22:34:06.707Z"
locales:
  - [en](https://longbridge.com/en/quote/AFP.AU/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AFP.AU/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AFP.AU/news.md)
---

# AFP.AU (AFP.AU) — Related News

### [AFT Pharmaceuticals Targets Minimum $300m Revenue After Record Earnings](https://longbridge.com/en/news/287149533.md)
*2026-05-21T02:52:54.000Z*
> AFT Pharmaceuticals aims for over $300 million in revenue by FY27 after reporting record earnings and 22% revenue growth

### [AFT Pharmaceuticals appoints new CFO to support global growth](https://longbridge.com/en/news/286682956.md)
*2026-05-17T21:17:14.000Z*
> AFT Pharmaceuticals has appointed Stuart Houliston as the new CFO, effective June 15, 2026, succeeding Malcolm Tubby. Ho

### [New Zealand Stocks Track Wall Street Higher](https://longbridge.com/en/news/281805031.md)
*2026-04-06T22:52:58.000Z*
> The NZX 50 rose 93 points (0.7%) to 12,996 in morning trade, following a two-day Easter closure and extending previous g

### [Bafna Pharmaceuticals Shuts Trading Window Ahead of FY26 Results](https://longbridge.com/en/news/280606113.md)
*2026-03-26T09:56:35.000Z*
> Bafna Pharmaceuticals Shuts Trading Window Ahead of FY26 Results

### [AFT Pharmaceuticals faces change in CFO succession plan](https://longbridge.com/en/news/280225019.md)
*2026-03-23T23:17:15.000Z*
> AFT Pharmaceuticals faces change in CFO succession plan

### [AFT Pharmaceuticals Wins Appeal in Pascomer Profit-Sharing Dispute](https://longbridge.com/en/news/278280735.md)
*2026-03-08T20:52:17.000Z*
> AFT Pharmaceuticals has won a Court of Appeal ruling in New Zealand, dismissing PBL Solutions' claim for profit-sharing 

### [Faron's Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026](https://longbridge.com/en/news/276573595.md)
*2026-02-23T07:35:50.000Z*
> Faron Pharmaceuticals Ltd. announced that data from its Phase I/II BEXMAB trial on bexmarilimab, in combination with aza

### [NZX 50 Jumps 1.3% at Finish](https://longbridge.com/en/news/276298920.md)
*2026-02-19T03:59:23.000Z*
> The NZX 50 rose 1.3%, closing at 13,420, driven by gains in financials, healthcare, non-energy minerals, and logistics. 

### [Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma](https://longbridge.com/en/news/273804282.md)
*2026-01-27T07:29:09.000Z*
> Faron Pharmaceuticals has expanded its clinical trials for bexmarilimab, an investigational immunotherapy, to include a